A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

PHASE1CompletedINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL

CVX-096

Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg

Trial Locations (2)

Cetero Research, Miami Gardens

Cetero Research - San Antonio, San Antonio